UMMS Affiliation

Center for Health Policy and Research; Clinical Pharmacy Services; Commonwealth Medicine

Publication Date

2017-03-27

Document Type

Poster

Disciplines

Health Services Administration | Health Services Research | Pharmacy and Pharmaceutical Sciences | Virus Diseases

Abstract

An evaluation of the effectiveness of HCV genotype 1 treatment with Harvoni® (ledipasvir/sofosbuvir) as measured by a sustained virological response (SVR) of 12 weeks in the MassHealth fee-for-service and Primary Care Clinician plan population. The analysis concluded that treatment was associated with a a high rate of SVR12, which means that Hepatitis C is not detected in the blood after 12 weeks.

Keywords

Hepatitis C, Harvoni, ledipasvir, sofosbuvir, HCV genotype 1

Rights and Permissions

© 2017 University of Massachusetts Medical School

DOI of Published Version

10.13028/af0c-5q14

Journal/Book/Conference Title

2017 Academy of Managed Care and Specialty Pharmacy Annual Conference

Comments

Presented at the Academy of Managed Care and Specialty Pharmacy Annual Conference 2017.

Share

COinS